Acute kidney injury is the most frequent complication in patients with septic shock and is an independent risk factor for death. Although renal-replacement therapy is the standard of care for severe acute kidney injury, the ideal time for initiation remains controversial.
T h e ne w e ngl a nd jou r na l o f m e dicine A cute kidney injury is a frequent complication in patients hospitalized in the intensive care unit (ICU) for septic shock [1] [2] [3] and is associated with high mortality. [3] [4] [5] [6] [7] Acute kidney injury associated with sepsis is characterized by a distinct pathophysiology, 8 and patients with acute kidney injury and septic shock may have a different response to renalreplacement therapy than patients with acute kidney injury without septic shock. 9 In managing severe acute kidney injury, whether to provide renal-replacement therapy and, if so, when to initiate it are unclear. It is widely accepted that if there are life-threatening complications of acute kidney injury, such as hyperkalemia or metabolic acidosis, renal-replacement therapy should be initiated immediately. However, in the absence of such complications, the appropriate timing of the initiation of renal-replacement therapy remains unclear. Some clinical investigators have explored strategies of very early renalreplacement therapy to treat the initial phase of septic shock, but in reports of such efforts, hemofiltration techniques were introduced, irrespective of the presence of renal failure. 10, 11 Recently, two randomized, controlled trials comparing an early strategy with a delayed strategy for the initiation of renal-replacement therapy reported conflicting results. 12, 13 Thus, whether there is a benefit to early initiation of renal-replacement therapy is not established, and the magnitude of the risk (if any risk exists) associated with delaying the initiation of renal-replacement therapy in the setting of acute kidney injury associated with sepsis is not known. Here we report the results of a randomized, multicenter, controlled trial that we performed to investigate the effect on 90-day mortality of the timing of the initiation of renal-replacement therapy in patients with septic shock and severe acute kidney injury.
Me thods

Trial Design
The Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit (IDEAL-ICU) trial was a randomized, controlled, open-label, multicenter trial that was designed to compare an early strategy with a delayed strategy for the initiation of renal-replacement therapy in the management of severe acute kidney injury in patients in the initial phase of septic shock. (Trial definitions are provided in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.) The trial design has been reported previously; the protocol is available at NEJM.org. 14 With the early strategy, renal-replacement therapy was started within 12 hours after the onset of acute kidney injury that was determined to be at the failure stage of the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification (see the Box in the Supplementary Appendix). 15 With the delayed strategy, renal-replacement therapy was initiated after a delay of 48 hours if renal function did not spontaneously recover and if no condition meeting the criteria for emergency renal-replacement therapy developed.
Trial Oversight
The University Hospital of Dijon, France, supervised the use of the trial funding. An independent data and safety monitoring board reviewed safety data and results at two planned interim analyses. This trial received approval for all participating centers from the Dijon ethics committee (Comité de Protection des Personnes Est I). The trial was overseen by a trial management committee. The first author wrote the first draft of the manuscript, which was reviewed by the management committee. Statistical analyses were performed by the trial statistician in accordance with International Conference on Harmonisation Good Clinical Practice guidelines. The authors vouch for the accuracy and completeness of the reported analyses and for the fidelity of the trial to the protocol. There was no commercial support for the trial. Further details are provided in the Supplementary Appendix.
Trial Population
Patients were eligible if they were 18 years of age or older, were admitted to the ICU in the early phase of septic shock (within 48 hours after the start of vasopressor therapy), and had acute kidney injury meeting at least one of the following criteria for the failure stage of the RIFLE classification: oliguria (urine output <0.3 ml per kilogram of body weight per hour for ≥24 hours), anuria for 12 hours or more, or a serum creatinine level 3 times the baseline level ( Table S2 in the Supplementary Appendix.
Randomization
Randomization was performed by means of an online response system, with the use of Tenalea software (FormsVision BV), during the first 48 hours of septic shock after acute kidney injury was determined to be at the failure stage of the RIFLE classification. Randomization was performed on the basis of a minimization technique with stratification according to center, age, Sepsis-related Organ Failure Assessment (SOFA) score (which ranges from 0 to 24, with higher scores indicating more severe organ failure), 16 site, and type of infection. Patients were randomly assigned to the early-strategy group or the delayed-strategy group in a 1:1 ratio. The INSERM Clinical Epidemiology Unit (Centre d'Investigation Clinique 1432 in Dijon, France) managed the data and generated blinded reports for the data and safety monitoring board.
Interventions
In the early-strategy group, renal-replacement therapy was initiated within 12 hours after documentation of failure-stage acute kidney injury. Patients assigned to the delayed-strategy group were closely monitored after randomization to detect the development of any one of the following conditions included in the criteria for emergency renal-replacement therapy: hyperkalemia (potassium level >6.5 mmol per liter), metabolic acidosis (pH <7.15), or fluid overload (extravascular fluid overload that was refractory to diuretics, with pulmonary edema). If any of these conditions occurred, renal-replacement therapy was initiated as soon as possible. If none of these conditions occurred, renal-replacement therapy was initiated in this group 48 hours after the diagnosis of acute kidney injury. Renalreplacement therapy was not initiated in the delayed-strategy group if spontaneous renal recovery occurred (defined as a decrease in creatinine level and a return of spontaneous urine output to >1000 ml per 24 hours [or >2000 ml per 24 hours in patients receiving diuretics]). The choice of renal-replacement therapy technique (intermittent or continuous) was at the discretion of clinical experts at each site, but participating clinicians were required to adhere to protocol instructions for settings and monitoring, which were based on international guidelines 17, 18 (see Table S3 in the Supplementary Appendix). In both groups, discontinuation of renal-replacement therapy was considered if renal recovery occurred, as defined above.
Trial Outcomes
The primary outcome was death from any cause at 90 days after randomization. Secondary outcomes were death at 28 days and at 180 days; the number of days free of renal-replacement therapy, mechanical ventilation, and vasopressors at 28 days after randomization; the length of stay in the ICU and in the hospital; adverse events during the entire ICU stay, with a focus on the complications potentially related to acute kidney injury or renal-replacement therapy during the first 7 days after enrollment; fluid balance in the first 7 days after enrollment; the need for emergency renal-replacement therapy in the delayedstrategy group; death of patients in the delayedstrategy group in whom at least one criterion for emergency renal-replacement therapy was met; and dependence on renal-replacement therapy at hospital discharge.
Statistical Analysis
Considering that death at 90 days was a binary outcome and assuming that mortality would be 10 percentage points lower in the early-strategy group than in the delayed-strategy group (45% vs. 55%) and that 5% of the patients would not be able to be evaluated, we estimated that 864 patients (432 per group) would need to be enrolled to provide 80% power at a two-sided alpha level of 0.05. Two interim efficacy analyses were planned (see the Interim Analyses section in the Supplementary Appendix). In both interim analyses, the frequency of death at 90 days after randomization in the two groups was compared with the chi-square test, at an alpha level of 0.0001 19 T h e ne w e ngl a nd jou r na l o f m e dicine to avoid changing the level of significance of the final primary analysis.
The primary analysis was performed according to the intention-to-treat principle. Categorical variables are expressed as numbers and percentages; continuous variables are expressed as means and standard deviations or medians and interquartile ranges as appropriate. Both categorical and continuous variables were compared in bivariate analyses with the use of corresponding tests. For the main comparison between the two groups of the proportion of deaths at 90 days, we used a chi-square test. A logistic-regression analysis with further stratification according to center was performed with adjustment for baseline prognostic factors (the presence or absence of chronic renal failure and exposure or nonexposure to hydroxyethyl starch in the 24 hours before randomization).
In secondary analyses, the proportion of deaths at 28 days and at 180 days was assessed and the corresponding survival probabilities were plotted with the use of the Kaplan-Meier method. The time from documentation of acute kidney injury to initiation of renal-replacement therapy, the length of ICU and hospital stay, and the number of days free of mechanical ventilation, vasopressors, and renal-replacement therapy are expressed as medians and interquartile ranges and were compared with the use of the Mann-Whitney test. We evaluated safety by calculating the percentage of patients in the two groups in whom the criteria for emergency renal-replacement therapy were met and the percentage with severe metabolic disorders, pulmonary edema due to fluid overload, arterial hypotension requiring an increase in vasopressor dose or a reintroduction of vasopressors, severe symptomatic cardiac arrhythmias, and severe hemorrhage; percentages were compared with the use of appropriate tests.
Analyses were performed with SAS software, version 9.3 (SAS Institute). The significance level was set at 0.05 for all analyses. Given the negative primary outcome, secondary outcomes should be regarded as exploratory and should not be used for inferences about treatment differences.
R esult s
Enrollment
The trial was conducted from July 2012 through October 2016 in 29 ICUs (22 university teaching hospitals and 7 general hospitals) in France. A total of 1728 of the patients who were assessed were eligible for inclusion, of whom 488 underwent randomization; 246 patients were assigned to the early-strategy group and 242 to the delayedstrategy group (Fig. 1) . After the second interim analysis, the independent data and safety monitoring board deemed that completion of enrollment was unlikely to change the results of the trial significantly and recommended that the trial be stopped. The conditional power calculated at the second interim analysis, when termination of the trial owing to futility was recommended, was 51.44% (details are provided in the Interim Analyses section in the Supplementary Appendix).
Baseline Characteristics
There were no significant differences in baseline characteristics between the groups (Table 1, and  Table S4 in the Supplementary Appendix). In addition, diagnostic criteria for acute kidney injury did not differ between the two groups. The frequency of chronic renal failure was higher in the delayed-strategy group, and exposure to nephrotoxic agents was higher in the early-strategy group, but neither difference was significant.
Initiation of Renal-Replacement Therapies
Nearly all patients assigned to the early-strategy group received renal-replacement therapy (239 of 246 patients [97%]). In the delayed-strategy group, 149 of 242 patients (62%) received renal-replacement therapy; of the remaining 93 patients, 70 (29%) did not receive renal-replacement therapy because they had spontaneous recovery of renal function, 21 (8%) died before renal-replacement therapy was initiated, and 2 (1%) did not receive renal-replacement therapy for other reasons (Table S5 in the Supplementary Appendix).
The median time from diagnosis of acute kidney injury to initiation of renal-replacement therapy was 7.6 hours (interquartile range, 4.4 to 11.5) in the early-strategy group and 51.5 hours (interquartile range, 34.6 to 59.5) in the delayedstrategy group (P<0.001). Criteria for emergency renal-replacement therapy were met in 41 patients in the delayed-strategy group (17%), who thus received renal-replacement therapy before the 48-hour delay had taken place. Patient characteristics at the time of initiation of renal-replacement therapy are provided in Table S6 in the Supplementary Appendix.
Renal-Replacement Ther apy in Acute Kidney Injury
Primary Outcome
Follow-up data at 90 days were available for 477 patients (98%). The early initiation of renalreplacement therapy did not result in lower mortality at 90 days than the delayed strategy; 138 of 239 patients (58%) in the early-strategy group died and 128 of 238 patients (54%) in the delayed-strategy group died (P = 0.38) ( Table 2) .
Further stratification according to center and adjustment for preexisting chronic renal failure and exposure to nephrotoxic agents did not change the results.
Secondary Outcomes
The delayed strategy resulted in a significantly larger number of days free of renal-replacement Fluid balance before enrollment -ml/24 hr 3194±2352 3211±2244
* Plus-minus values are means ±SD. There were no significant between-group differences in the characteristics at baseline. To convert the values for creatinine to micromoles per liter, multiply by 88.4. To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357. ICU denotes intensive care unit, and IQR interquartile range. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ This category includes patients who had a New York Heart Association class of III or IV. § The Simplified Acute Physiology Score (SAPS) II ranges from 0 to 163, with higher scores indicating more severe disease and a higher risk of death. ¶ The Sepsis-related Organ Failure Assessment (SOFA) score ranges from 0 to 24, with higher scores indicating more severe organ failure. ‖ The failure stage of the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification is defined as a serum creatinine level 3 times the baseline level (or ≥4 mg per deciliter with a rapid increase of ≥0.5 mg per deciliter), oliguria (urine output <0.3 ml per kilogram of body weight per hour for ≥24 hours), or anuria for 12 hours or more. ** The baseline serum creatinine level either was determined with the use of values measured in the 12 months preceding the ICU stay or was estimated. interquartile range, 1 to 25) (P = 0.006). There were no significant differences between the groups in the other secondary outcomes, namely mortality at 28 days and 180 days, number of days free of mechanical ventilation and vasopressors, and length of ICU and hospital stay ( Table 2, and Table S7 in the Supplementary Appendix). Overall survival estimated with the Kaplan-Meier method is shown in Figure 2 . The rate of dependence on renal-replacement therapy among survivors at 28 days did not differ significantly between the groups (13% in the earlystrategy group and 12% in the delayed-strategy group; P = 0.89). Details of renal-replacement therapy techniques and settings are provided in Table S8 in the Supplementary Appendix.
Safety
In the delayed-strategy group, a condition meeting at least one criterion for emergency renalreplacement therapy developed in 41 patients (17%); 28 of these patients died. Metabolic abnormalities observed in the first 7 days after enrollment were more common in the delayedstrategy group than in the early-strategy group; 9 patients (4%) in the delayed-strategy group had severe hyperkalemia (with a median potassium level of 7.0 mmol per liter [interquartile range, 6.7 to 7.3]), whereas no patients in the earlystrategy group had hyperkalemia (P = 0.03) ( Table 3 ). There were no significant differences between the groups in other adverse events.
Fluid Balance
There was no significant difference between the groups in fluid balance in the 24 hours before randomization, in the 48 hours after enrollment, or at 7 days. Details are provided in Table S9 in the Supplementary Appendix.
Discussion
Our trial addressed the question of the timing of renal-replacement therapy specifically in a homogeneous population of patients with severe acute kidney injury who were in the early phase of septic shock. In this population, a strategy of early initiation of renal-replacement therapy did not result in lower mortality at 90 days than a strategy in which initiation of renal-replacement therapy was delayed by 48 hours. There was less use of renal-replacement therapy in the delayedstrategy group; 38% of patients did not undergo renal-replacement therapy (75% of these patients had spontaneous recovery of renal function). The overall mortality was 55%, corresponding exactly to our working hypothesis, which was based on published data. [4] [5] [6] [7] Recently, two randomized, controlled trials 12, 13 explored the question of the timing of initiation of renal-replacement therapy, but their results were conflicting. Our results are similar to those reported by Gaudry and colleagues, 12 who enrolled more than 600 patients who were admitted to the ICU with acute kidney injury of Kidney Disease: Improving Global Outcomes (KDIGO) classification stage 3 (serum creatinine 3 times the baseline level or ≥4 mg per deciliter, urine output <0.3 ml per kilogram per hour for ≥24 hours, or anuria for ≥12 hours; stages range from 1 to 3, with higher stages indicating more severe kidney injury); they found no significant difference in mortality at 60 days when comparing a strategy of early renal-replacement therapy with a delayed strategy in which renal-replacement therapy was initiated only if prespecified criteria were met. A post hoc analysis involving 348 patients with septic shock (56% of the overall population) had similar results. 20 The second trial 13 was a single-center, randomized, controlled trial that enrolled 231 patients with acute kidney injury of KDIGO stage 2 (serum creatinine level 2.0 to 2.9 times the baseline level or urine output <0.5 ml per kilogram per hour for ≥12 hours) and showed the opposite result -significantly lower mortality at 90 days in the group assigned to early initiation than in the group assigned to delayed initiation. Differences in inclusion criteria and dialysis techniques might explain the discrepancies in the results between that trial and our current trial.
The potential advantage of earlier initiation of dialysis in acute kidney injury is that it may improve acid-base, electrolyte, and fluid balance, thereby preventing more severe complications of acute kidney injury and perhaps also enhancing removal of toxins. 21 However, in our trial we did not observe lower mortality with early initiation than with delayed initiation. Thus, our results did not confirm our hypothesis that a strategy of early renal-replacement therapy could improve fluid balance and outcomes in this specific population. A possible explanation is that fluid removal with renal-replacement therapy cannot be performed easily or safely in patients with hemodynamic instability in the early phases of septic shock, so starting such therapy earlier would not improve fluid balance. Our results show that initiating renal-replacement therapy too early could unnecessarily expose patients in whom renal dysfunction would have recovered spontaneously to the risks associated with renal-replacement therapy. Indeed, 29% of the patients in the delayed-strategy group did not require renal-replacement therapy because they had spontaneous recovery of renal function, although 26% of these patients (18 of 70 patients) subsequently died, which is similar to rates reported in other studies. 22 It is possible that more patients might have recovered without renal-replacement therapy if the delay had been longer than 48 hours, as was observed in a recent study. 12 Mortality was higher among patients assigned to the delayed-strategy group who met criteria for emergency renal-replacement therapy (68% [28 of 41 patients]) than among those who did not meet the criteria. However, the development of these complications may be identifying a subgroup of patients with more severe underlying disease, and we cannot conclude that death was related to the delay in renal-replacement therapy or that earlier initiation of renalreplacement therapy would have saved a given patient.
Although our trial did not show any benefit to expediting the initiation of renal-replacement therapy in the absence of emergency criteria, our Hyperkalemia was defined as a potassium level of more than 6.5 mmol per liter with characteristic electrocardiographic changes. The median pH and median potassium values were calculated only in patients who underwent renal-replacement therapy because they met these specific criteria. Fluid overload was defined as extravascular fluid overload that was refractory to diuretics, with pulmonary edema. Other reasons included worsening of the patient's clinical status, with acidosis and hyperkalemia below the prespecified threshold, associated with hyperlactatemia, with the need for emergency renal-replacement therapy as determined by the clinician treating the patient. § Other criterion was worsening of multiple organ failure that mandated the initiation of renal-replacement therapy in the opinion of the clinician caring for the patient, confirmed by an increase of at least 2 points in the SOFA score (not a prespecified criterion for emergency renal-replacement therapy). ¶ The number of days free of renal-replacement therapy, mechanical ventilation, or vasopressor therapy was calculated according to the number of days the patient was alive without the intervention at day 28; patients who died were assigned zero free days. ‖ In patients who received renal-replacement therapy, the renal component of the SOFA score was calculated on the basis of urine output only. ** Creatinine values are for all living patients who were no longer receiving renal-replacement therapy. In the early-strategy group, renal-replacement therapy was initiated within 12 hours after documentation of acute kidney injury. In the delayed-strategy group, renal-replacement therapy was initiated 48 hours after the documentation of acute kidney injury, if renal recovery had not occurred. If criteria for emergency renal-replacement therapy were met by a patient in this group, renal-replacement therapy was initiated as soon as possible. The tick marks indicate censored data. The P value is for the comparison of overall survival between the two groups. Other metabolic complication** 9 (4) 8 (3) 0.83 * Metabolic acidosis was defined as a pH of less than 7.15 and a base deficit of more than 5 mmol per liter or a bicarbonate level of 18 mmol or less per liter. † Hyperkalemia was defined as a potassium level of more than 6.5 mmol per liter with characteristic electrocardiographic changes. ‡ Fluid overload was defined as extravascular fluid overload that was refractory to diuretics with pulmonary edema. § Severe cardiac-rhythm disorders were defined as ventricular tachycardia, ventricular fibrillation, torsades de pointes, third-degree atrioventricular block, or extreme bradycardia requiring medical treatment. ¶ Severe bleeding events were defined as the need for transfusion of 3 or more consecutive units of packed red cells in the same day. Minor bleeding events were defined as the need for transfusion of less than 3 units of packed red cells in the same day. ‖ Hypotensive episodes during renal-replacement therapy were defined as a mean arterial pressure of 55 mm Hg or less and an increase in vasopressor dose or a reintroduction of vasopressors. The frequency of this adverse event was calculated only in patients who underwent renal-replacement therapy. ** Other metabolic complications were defined as severe hypophosphatemia (serum phosphate <0. results cannot be interpreted as encouraging indefinite deferral of renal-replacement therapy. Rather, our data indicate that the risk of death is not increased if renal-replacement therapy is postponed for at least 48 hours, as long as care is taken to identify patients in whom criteria for emergency renal-replacement therapy are likely to be met. Our trial has certain limitations. First, we used the failure stage of the RIFLE classification to identify eligible patients. RIFLE was the most commonly used classification for the identification of patients with acute kidney injury at the time the trial was designed. However, studies have shown that RIFLE is not as sensitive as the most recent classification system. Moreover, the failure stage was not necessarily intended to identify patients who would require renal-replacement therapy. The second limitation is the choice of a delay of only 48 hours, which may not be sufficiently long to allow recovery of renal function in some patients or to detect a difference between early and delayed initiation of renal-replacement therapy. However, we thought that a longer delay would be unethical and unsafe for patients who actually needed renal-replacement therapy.
Proportion Surviving
In conclusion, this trial showed no significant difference in mortality between a strategy of early initiation of renal-replacement therapy and a strategy of delayed initiation in patients with septic shock and severe acute kidney injury but with no immediate, life-threatening complications linked to acute kidney injury.
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